Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celsion Corporation
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Company plans to pursue accelerated approval based on a single-arm registrational study of PD-1 failures, after reporting positive results from a Phase II study at the ASCO-SITC meeting.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Celsion plans to bring its first-line immune-oncology drug into clinical studies in China in 2018, with the help from its long-term local partner Zhejiang Hisun Pharmaceuticals. The partnership with Hisun serves multiple strategic purposes for lower costs and quicker approvals in the country where immunotherapeutics is becoming hot new category of cancer treatment.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Egen, Inc.
- Expression Genetics